RELMADA THERAPEUTICS, INC. 10-K

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Market Information Our common stock is listed on Nasdaq Global Select Market, under the symbol “RLMD”. Holders As of March 21, 2022, 29,369,490 shares of common stock were issued and outstanding, which were held by 154 holders of record. These stockholders held their stock either individually or in nominee or “street” names through various brokerage firms. There are no shares of our Class A convertible preferred stock outstanding. Our transfer agent is: Empire Stock Transfer 1859 Whitney Mesa Drive Henderson, NV 89014 Telephone (702) 818-5898 www.empirestock.com Inquiries regarding stock transfers, lost certificates or address changes should be directed to the above address. Dividends We plan to retain any earnings for the foreseeable future for our operations. We have never paid any cash dividends on our stock and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our Board of Directors and will depend on our financial condition, operating results, capital requirements and such other factors as our Board of Directors deems relevant. Securities Authorized for Issuance under Equity Compensation Plans Relmada has a 2014 Option and Equity Incentive Plan, as amended (the Plan) in which its directors, officers, employees and consultants shall be eligible to participate. The Plan allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company. On May 20, 2021, at the annual shareholders meeting, our shareholders approved our 2021 Equity Incentive Plan (the 2021 Plan) which allows for the granting of incentive and nonqualified stock options, stock appreciation rights, restricted stock awards, performance share awards and other equity-based awards for up to 1,500,000 shares of our common stock to directors, officers, employees and consultants. At the annual shareholders meeting (currently anticipated for mid-May, 2022), our shareholders will vote on a management proposal to increase the shares authorized for awards under the 2021 Plan by 3,900,000 shares but there can be no assurance such amendment will be approved. With these grants and approvals, as of December 31, 2021, the Company had 222,320 awards available to be issued. The following table summarizes our equity compensation plan information as of December 31, 2021: Equity Compensation Plan Information Plan Category Number of securities to be issued upon exercise of outstanding options and stock appreciation rights Weighted- average exercise price of outstanding options and stock appreciation rights Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (a) (b) (c) Equity compensation plans approved by security holders 10,330,622 $ 22.52 222,320 Equity compensation plans not approved by security holders - - - Total 10 ,330,622 $ 22.52 222,320 33 ITEM 6. [RESERVED]